Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.
You may also be interested in...
Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't
Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.
Keeping Track: Submissions Galore, And Still More 'Breakthroughs'
The latest drug development news and highlights from our FDA Performance Tracker.
Eisai’s Lenvima Gets CHMP Backing, Nexavar Marketing Rivalry Looms
Other medicines receiving positive opinions from the EU’s top scientific advisory panel after its March meeting include Helsinn’s Akynzeo for chemotherapy associated nausea and vomiting, the first 9-valent HPV vaccine, Sanofi Pasteur MSD’s Gardasil 9, and Boehringer Ingelheim’s Synjardy combination of empagliflozin and metformin.